167
In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).
 patients: Subject; bleeding incidence: Effect; antithrombin III and concomitant heparin: Treatment; concomitant heparin: Treatment.Drug; antithrombin III: Treatment.Drug; antithrombin III: Combination.Drug; concomitant heparin: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients: Subject; bleeding incidence: Effect; antithrombin III and concomitant heparin: Treatment; concomitant heparin: Treatment.Drug; antithrombin III: Treatment.Drug; antithrombin III: Combination.Drug; concomitant heparin: Combination.Drug